Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study

Academic Article

Publication Date:

2017

Short description:

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study / Brandes, ., A., A., Finocchiaro, ., Zagonel, ., Reni, M., Fabi, ., Caserta, ., Tosoni, ., Eoli, ., Lombardi, ., Clavarezza, ., Paccapelo, ., Bartolini, ., Cirillo, ., Agati, ., Franceschi,. - In: ONCOTARGET. - ISSN 1949-2553. - (2017).

Iris type:

1.1 Articolo in rivista

List of contributors:

Brandes, ; A., A.; Finocchiaro, ; Zagonel, ; Reni, M; Fabi, ; Caserta, ; Tosoni, ; Eoli, ; Lombardi, ; Clavarezza, ; Paccapelo, ; Bartolini, ; Cirillo, ; Agati, ; Franceschi,

Authors of the University:

RENI MICHELE

Handle:

https://iris.unisr.it/handle/20.500.11768/123783

Published in:

ONCOTARGET

Journal